OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: ***The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.***

Drug Requested: Venclexta™ (venetoclax)

DRUG INFORMATION: Complete information below. If incomplete, authorization process will be delayed

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ ***ICD Code, if applicable:*** _____

CLINICAL CRITERIA: ALL boxes MUST be checked to qualify. Incomplete information will delay authorization process.

- ❑ Diagnosis of chronic lymphocytic leukemia (CLL)

  AND

- ❑ Confirmation of the presence of 17p deletion as detected by an FDA approved test

  AND

- ❑ Failure or clinically significant adverse effects to at least one previous therapy:
  - ❑ Imbruvica® (ibrutinib)
  - ❑ High dose methylprednisolone + rituximab (Rituxan®)
  - ❑ Fludarabine, cyclophosphamide, rituximab (FCR)
  - ❑ Fludarabine + rituximab (FR)
  - ❑ Gazyva® (obinutuzumab) + chlorambucil
  - ❑ Campath® (alemtuzumab) + rituximab
  - ❑ Zydelig® (idelalisib) +/- rituximab

***Medication being provided by a Specialty Pharmacy*:** ❑ **Briova SpecialtyRx**

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. *****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

***Approved by Pharmacy and Therapeutics Committee:** 5/18/2017;
REVISED/UPDATED: ~~6/29/2017~~; ~~9/18/2017~~; **10/7/2017**;